Naproxen

also known as Naproxen sodium · Aleve · Naprosyn · BAYH6689 · OXP005 · BAY117031 · BAYH006689 · Anaprox · +46 more

Small molecule targets TAS1R3 via inhibition

Developed for: migraine disorder · osteoarthritis · osteoarthritis, knee · juvenile idiopathic arthritis · neuropathy, painful · Alzheimer disease · arthritic joint disease · chronic pain syndrome
+43 more
· dysmenorrhea · gastric ulcer · gout · Lynch syndrome · osteoarthritis, hip · peptic ulcer disease · rheumatoid arthritis · temporomandibular joint disorder · ankylosing spondylitis · bone pain, periodic · cellulitis · COVID-19 · dental abscess · hemorrhagic disease · ligament disorder · lumbar disk disease · migraine without aura · mucositis · musculoskeletal system disorder · obsessive-compulsive disorder · oral cavity squamous cell carcinoma · perineocele · pleural neoplasm · primary dysmenorrhea · sciatica · spondyloarthropathy · tendinosis · tooth disorder · traumatic myositis ossificans · abdominal aortic aneurysm · colorectal cancer · epicondylitis · essential hypertension · frozen shoulder · immune reconstitution inflammatory syndrome · menstrual disorder · migraine with aura · myositis ossificans · osteoarthritis, hand · periodontitis · pharyngitis · traumatic encephalopathy · urolithiasis
Investigated by: Bayer · GlaxoSmithKline · POZEN · Pfizer · AstraZeneca · Johnson & Johnson Consumer Inc. (J&JCI)
+121 more
· Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · Merck Sharp & Dohme LLC · National Cancer Institute (NCI) · Bispebjerg Hospital · Boehringer Ingelheim · Endeavor Health · Massachusetts General Hospital · McMaster University · National Institute on Aging (NIA) · National Institutes of Health (NIH) · Northwestern University · Oxford Pharmascience Ltd · Regeneron Pharmaceuticals · Sen-Jam Pharmaceutical · São Paulo Research Foundation · Teva Pharmaceutical Industries, Ltd. · University of Pennsylvania · University of Washington · Viatris Inc. · Abdi Ibrahim Ilac San. ve Tic A.S. · Alzheimer's Disease Cooperative Study (ADCS) · American College of Obstetricians and Gynecologists · Amgen · Ankara City Hospital Bilkent · Ardea Biosciences, Inc. · Assistance Publique - Hôpitaux de Paris · Astellas Pharma Inc · Azad University of Medical Sciences · Beijing Friendship Hospital · Biogen · Cady, Roger, M.D. · Canadian Department of National Defence · Chittagong Medical College · Cliantha Research · Daewoong Pharmaceutical Co. LTD. · Desiree Neville, MD · Deutsche Sporthochschule Köln · Diskapi Yildirim Beyazit Education and Research Hospital · Eurofarma Laboratorios S.A. · Fatima Memorial Hospital · Federal University of Sergipe · Gary Morrow · Giovana Maria Weckwerth · HK inno.N Corporation · Hamilton Health Sciences Corporation · Helse Stavanger HF · Hersh, Elliot V., DMD, MS, PhD · Iffat Anwar Medical Complex · Iroko Pharmaceuticals, LLC · Istanbul Medeniyet University · JW Pharmaceutical · Janssen Research & Development, LLC · Jiangsu Provincial People's Hospital · Johns Hopkins University · Johnson & Johnson Consumer and Personal Products Worldwide · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Kantonsspital Graubünden · King's College London · LG Chem · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · M.D. Anderson Cancer Center · Mayo Hospital Lahore · McMaster Surgical Associates · McNeil AB · Mclean Hospital · Monell Chemical Senses Center · Montefiore Medical Center · National Center for Advancing Translational Sciences (NCATS) · National Center for Complementary and Integrative Health (NCCIH) · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of General Medical Sciences (NIGMS) · Northwell Health · Onconic Therapeutics Inc. · Ontario Institute for Cancer Research · all 127 on the full record

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	ANAPROX DS	—	1987-09-30	fda.gov ↗
Label expansions (2)	US (FDA)	NAPROSYN	—	1980-07-15 – 1987-03-23	fda.gov ↗
Approved	US (FDA)	NAPROSYN	—	1976-03-11	fda.gov ↗

Trials 148 · started per year

today

US approved 1976

1975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT00830050	Jul → Dec 2010	osteoarthritis	Pfizer	Completed	No outcome recorded
Phase 138 trials
Phase 1	NCT07277712	Dec 2025 → May 2026 overdue	—	HK inno.N Corporation	Not yet recruiting	No outcome recorded
Phase 1	NCT06511973	Jul → Aug 2024	—	Bayer	Completed	No outcome recorded
Phase 1	NCT06415019	Jun → Aug 2024	—	Bayer	Completed	No outcome recorded
Phase 1	NCT06435442	Jun 2024 → Dec 2025	—	JW Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT05844995	Sep 2023 → Feb 2024	—	Johnson & Johnson Consumer Inc. (J&JCI)	Completed	No outcome recorded
Phase 1	NCT05181124	Mar 2021	active peptic ulcer disease	Onconic Therapeutics Inc.	Completed	No outcome recorded
Phase 1	NCT04490434	Jun → Aug 2020	—	Daewoong Pharmaceutical Co. LTD.	Unknown	No outcome recorded
Phase 1	NCT04139824	Jan → Feb 2020	gout	LG Chem	Completed	No outcome recorded
Phase 1	NCT03697889	Dec 2018	—	McNeil AB	Completed	No outcome recorded
Phase 1	NCT03424135	Mar → Apr 2018	—	Bayer	Completed	No outcome recorded
Phase 1	NCT03396250	Feb → Mar 2018	—	Bayer	Completed	No outcome recorded
Phase 1	NCT03183297	Aug → Oct 2017	—	Sen-Jam Pharmaceutical	Unknown	No outcome recorded
Phase 1	NCT03167541	Oct → Dec 2016	—	Reckitt Benckiser Healthcare (UK) Limited	Completed	No outcome recorded
Phase 1	NCT02502006	Nov 2015 → Sep 2022	—	University of Pennsylvania	Terminated	No outcome recorded
Phase 1	NCT02408978	May → Jun 2015	gastroduodenitis	Oxford Pharmascience Ltd	Completed	No outcome recorded
Phase 1	NCT02351024	Feb → Mar 2015	—	Oxford Pharmascience Ltd	Completed	No outcome recorded
Phase 1	NCT02229461	Feb → May 2015	hematologic disorder	Bayer	Completed	No outcome recorded
Phase 1	NCT02052908	Jan 2014 → Oct 2019	Lynch syndrome	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01884272	Jun → Aug 2013	gout	Ardea Biosciences, Inc.	Completed	No outcome recorded
Phase 1	NCT01659372	Jun → Dec 2012	temporomandibular joint disorder	Shahid Beheshti University	Unknown	No outcome recorded
Phase 1	NCT01358383	May → Jun 2011	juvenile idiopathic arthritis	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT01343303	Mar → Dec 2011	osteoarthritis, knee	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01094483	Mar → May 2010	platelet aggregation, spontaneous	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT01409603	Jan → May 2010	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00992381	Sep → Oct 2009	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00945178	Aug → Sep 2009	—	AstraZeneca	Terminated	No outcome recorded
Phase 1	NCT00933582	Aug 2009 → Jun 2010	osteoarthritis, knee	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 1	NCT00969449	Apr → May 2009	—	Bayer	Completed	No outcome recorded
Phase 1	NCT00818415	Nov 2008	—	Bayer	Completed	No outcome recorded
Phase 1	NCT00772967	Jun → Nov 2008	osteoarthritis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00676442	May → Jun 2008	arthritic joint disease	POZEN	Completed	No outcome recorded
Phase 1	NCT00751556	Feb → Mar 2008	—	Bayer	Completed	No outcome recorded
Phase 1	NCT00692016	Jan → Feb 2008	—	Bayer	Completed	No outcome recorded
Phase 1	NCT00596245	Oct → Dec 2007	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00442208	Jan 2007 → Feb 2008	—	POZEN	Completed	No outcome recorded
Phase 1	NCT00392080	Nov 2006 → Feb 2008	osteoarthritis	Pfizer	Completed	No outcome recorded
Phase 1	NCT00366262	Jun 2006 → Mar 2007	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 1	NCT00959439	Mar → May 2002	osteoarthritis, rheumatoid arthritis	Sandoz	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT07487909	Sep → Nov 2025	—	Sen-Jam Pharmaceutical	Completed	No outcome recorded
Phase 1/2	NCT01178203	Jul 2010	pulpitis	Azad University of Medical Sciences	Completed	No outcome recorded
Phase 216 trials
Phase 2	NCT05411718	Mar 2023 → Nov 2026 expected	Lynch syndrome	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT05026320	Aug → Dec 2021	—	Bayer	Completed	No outcome recorded
Phase 2	NCT05463367	Jan 2021 → Jun 2025 overdue	chronic pain syndrome, opiate dependence, substance abuse	Northwestern University	Active not recruiting	No outcome recorded
Phase 2	NCT04447040	Nov 2020 → Apr 2021	—	Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division	Completed	No outcome recorded
Phase 2	NCT04221165	Aug 2020 → Sep 2023	head and neck cancer, mucositis	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	No outcome recorded
Phase 2	NCT04115098	Jun 2020 → Aug 2023	spondyloarthropathy	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded
Phase 2	NCT04132336	Nov 2019 → Mar 2020	neuropathy, painful	Bayer	Completed	No outcome recorded
Phase 2	NCT03879408	May → Nov 2019	—	Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division	Completed	No outcome recorded
Phase 2	NCT03949673	Apr 2019 → Aug 2020	osteoarthritis, hip, osteoarthritis, knee	Regeneron Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT03570554	Jun 2018 → Jun 2019	osteoarthritis, knee	Bayer	Completed	No outcome recorded
Phase 2	NCT01612975	Apr 2014 → Jan 2018	pleural neoplasm	McMaster University	Terminated	No outcome recorded
Phase 2	NCT01712009	Nov 2012 → Mar 2015	bone pain, periodic	Amgen	Completed	No outcome recorded
Phase 2	NCT01229228	Oct 2010 → Apr 2011	—	Iroko Pharmaceuticals, LLC	Completed	No outcome recorded
Phase 2	NCT01147458	Jul 2010 → Feb 2011	osteoarthritis, knee	Pfizer	Terminated	No outcome recorded
Phase 2	NCT01102660	May 2010 → Feb 2011	osteoarthritis	Pfizer	Completed	No outcome recorded
Phase 2	NCT01231490	Sep 2008 → Jan 2009	osteoarthritis	GlaxoSmithKline	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT01016678	Mar 2010 → Jun 2014	migraine disorder	Premiere Research Institute	Completed	No outcome recorded
Phase 2/3	NCT00004845	? → Dec 2001	Alzheimer disease	National Institute on Aging (NIA)	Completed	No outcome recorded
Phase 341 trials
Phase 3	NCT07665476	Sep 2026 → Dec 2030 expected	cellulitis, skin infection	Ottawa Hospital Research Institute	Not yet recruiting	No outcome recorded
Phase 3	NCT05845008	Jan → Jul 2024	—	Johnson & Johnson Consumer Inc. (J&JCI)	Withdrawn	No outcome recorded
Phase 3	NCT05868122	Sep 2023 → May 2024	—	Johnson & Johnson Consumer Inc. (J&JCI)	Completed	No outcome recorded
Phase 3	NCT04384367	Dec 2022 → Oct 2024	migraine disorder	Eurofarma Laboratorios S.A.	Completed	No outcome recorded
Phase 3	NCT06948513	Dec 2022 → Jun 2023	—	Zitelli & Brodland Skin Cancer Center	Completed	No outcome recorded
Phase 3	NCT05485805	Sep 2022 → Jan 2024	—	Bayer	Completed	No outcome recorded
Phase 3	NCT04325633	Apr → Dec 2020	COVID-19	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 3	NCT04038346	Oct 2019 → May 2025	Lyme disease, arthritic joint disease	Desiree Neville, MD	Terminated	No outcome recorded
Phase 3	NCT03566979	Aug 2018 → Mar 2019	—	Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division	Completed	No outcome recorded
Phase 3	NCT04948164	Aug 2018 → Dec 2021	migraine disorder	Peking University Third Hospital	Unknown	No outcome recorded
Phase 3	NCT03161093	Aug 2017 → Sep 2019	osteoarthritis, hip, osteoarthritis, knee	Regeneron Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01939002	Nov 2013 → Oct 2015	multiple sclerosis	Biogen	Completed	No outcome recorded
Phase 3	NCT01495858	Dec 2011 → Feb 2012	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01427803	Sep → Dec 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01383486	Jul → Aug 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01389284	Jun → Sep 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01365052	May → Jul 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00844805	Sep 2009 → Apr 2011	ankylosing spondylitis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00809354	Feb 2009 → Oct 2010	osteoarthritis	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00843024	Dec 2008 → May 2010	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00751400	Jul → Nov 2008	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00720057	Jun → Aug 2008	dental abscess	Bayer	Completed	No outcome recorded
Phase 3	NCT00602420	Jun 2008 → Jan 2012	cancer of unknown primary site, musculoskeletal system disorder	Gary Morrow	Completed	No outcome recorded
Phase 3	NCT00665431	Apr → Dec 2008	osteoarthritis	POZEN	Completed	No outcome recorded
Phase 3	NCT00664560	Apr → Dec 2008	osteoarthritis	POZEN	Completed	No outcome recorded
Phase 3	NCT00573170	Feb 2008 → Aug 2009	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00594854	Sep 2007 → Sep 2008	gastric ulcer	POZEN	Terminated	No outcome recorded
Phase 3	NCT00488514	Jul 2007 → Aug 2009	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00527904	Mar 2007 → Mar 2009	gastric ulcer	POZEN	Completed	No outcome recorded
Phase 3	NCT00382993	Dec 2006 → Nov 2007	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00383162	Nov 2006 → Oct 2007	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00385008	Sep → Nov 2006	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00387881	Sep 2006 → Feb 2008	migraine without aura	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00329355	May → Nov 2006	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00329459	May → Nov 2006	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00433732	Aug 2004 → Apr 2005	migraine disorder	POZEN	Completed	No outcome recorded
Phase 3	NCT00434083	Jul 2004 → Jan 2005	migraine disorder	POZEN	Completed	No outcome recorded
Phase 3	NCT00175032	Jul 2003 → Jul 2004	osteoarthritis, peptic ulcer disease	Takeda	Completed	No outcome recorded
Phase 3	NCT00007189	Jan 2001 → May 2007	Alzheimer disease	Seattle Institute for Biomedical and Clinical Research	Completed	No outcome recorded
Phase 3	NCT00034853	Dec 2000 → Jun 2003	juvenile idiopathic arthritis	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00279747	Sep 2000 → Jan 2003	juvenile idiopathic arthritis	Boehringer Ingelheim	Completed	No outcome recorded

Phase 431 trials
Phase 4	NCT05900336	Mar 2024 → Aug 2025	dysmenorrhea	Mclean Hospital	Completed	No outcome recorded
Phase 4	NCT05722002	Feb 2023 → Dec 2026 expected	neuropathy, painful	University of Michigan	Recruiting	No outcome recorded
Phase 4	NCT05430230	Aug 2022 → Jun 2027 expected	osteoarthritis, knee	Northwestern University	Active not recruiting	No outcome recorded
Phase 4	NCT04694300	Feb 2021 → Aug 2022	—	Hersh, Elliot V., DMD, MS, PhD	Completed	No outcome recorded
Phase 4	NCT04015596	Oct 2020 → Apr 2025	autoimmune disease, obsessive-compulsive disorder	Massachusetts General Hospital	Terminated	No outcome recorded
Phase 4	NCT04307940	Mar → Oct 2020	—	Bayer	Completed	No outcome recorded
Phase 4	NCT04947566	Sep 2019 → Feb 2020	neuropathy, painful	Fatima Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT03697720	May 2018 → Nov 2020	dysmenorrhea	Endeavor Health	Completed	No outcome recorded
Phase 4	NCT03448536	Apr → Sep 2018	primary dysmenorrhea	Bayer	Completed	No outcome recorded
Phase 4	NCT04066426	Mar 2018 → Apr 2019	temporomandibular joint disorder	Yuzuncu Yil University	Completed	No outcome recorded
Phase 4	NCT03404206	Feb → Jul 2018	neuropathy, painful	Bayer	Completed	No outcome recorded
Phase 4	NCT03347929	Nov 2017 → Jun 2023	sciatica	Ostfold Hospital Trust	Completed	No outcome recorded
Phase 4	NCT03092193	Mar → Oct 2017	Amobarbital, deficient N-hydroxylation of	University of Sao Paulo	Completed	No outcome recorded
Phase 4	NCT04449471	Jan 2016 → Jul 2021	—	University of Washington	Unknown	No outcome recorded
Phase 4	NCT02667730	Jun 2015 → May 2019	ligament disorder	Canadian Department of National Defence	Completed	No outcome recorded
Phase 4	NCT02355236	Feb → Dec 2015	osteoarthritis	Severance Hospital	Unknown	No outcome recorded
Phase 4	NCT02281968	Dec 2014 → Dec 2015	—	Northwell Health	Withdrawn	No outcome recorded
Phase 4	NCT02494856	Oct 2014 → Dec 2015	impacted teeth, multiple	Giovana Maria Weckwerth	Completed	No outcome recorded
Phase 4	NCT02255955	Oct → Dec 2014	—	Diskapi Yildirim Beyazit Education and Research Hospital	Unknown	No outcome recorded
Phase 4	NCT02501564	May 2013 → Nov 2014	osteoarthritis	Istanbul Medeniyet University	Completed	No outcome recorded
Phase 4	NCT01071317	Feb 2010 → Jan 2012	migraine disorder	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT00807846	Sep 2009 → Dec 2012	juvenile idiopathic arthritis	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00893737	Jun 2009 → Jan 2010	migraine disorder	Cady, Roger, M.D.	Completed	No outcome recorded
Phase 4	NCT00792636	Nov 2008 → Nov 2009	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01118273	Jan → Feb 2008	—	Bayer	Completed	No outcome recorded
Phase 4	NCT00586365	Oct 2007 → Jan 2010	traumatic myositis ossificans	Massachusetts General Hospital	Withdrawn	No outcome recorded
Phase 4	NCT00222976	Sep 2006 → May 2007	perineocele	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT00137033	Sep 2004 → Jul 2005	peptic ulcer disease	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00410995	May 2004 → Aug 2006	—	University of Oklahoma	Terminated	No outcome recorded
Phase 4	NCT00157872	Jan → Jul 2004	rheumatoid arthritis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00261586	? → Mar 2004	—	Johnson & Johnson Consumer and Personal Products Worldwide	Completed	No outcome recorded

Phase not applicable17 trials
—	NCT07549490	Jul 2026 → Dec 2029 expected	—	National Center for Complementary and Integrative Health (NCCIH)	Not yet recruiting	No outcome recorded
—	NCT07606638	Feb → Jul 2026 overdue	oral cavity squamous cell carcinoma	Mayo Hospital Lahore	Enrolling by invitation	No outcome recorded
—	NCT06917118	May → Nov 2025 overdue	—	University of Puerto Rico	Not yet recruiting	No outcome recorded
—	NCT06453291	Jul 2024 → Apr 2025 overdue	chronic pain syndrome	Iffat Anwar Medical Complex	Recruiting	No outcome recorded
—	NCT06274151	Feb 2024 → Jul 2025 overdue	—	Bispebjerg Hospital	Not yet recruiting	No outcome recorded
—	NCT07706036	Jan → Jul 2024	—	Ankara City Hospital Bilkent	Completed	No outcome recorded
—	NCT04566250	Feb 2021 → Apr 2022	—	McMaster University	Completed	No outcome recorded
—	NCT05541185	Feb 2021	osteoarthritis, knee	Sultan ÇEÇEN	Completed	No outcome recorded
—	NCT06291337	Jun 2020 → Sep 2023	—	Rutgers, The State University of New Jersey	Completed	No outcome recorded
—	NCT05021718	Jul 2018 → Sep 2019	lumbar disk disease	Chittagong Medical College	Completed	No outcome recorded
—	NCT03401177	Jan 2018 → Jul 2019	tendinosis	Bispebjerg Hospital	Completed	No outcome recorded
—	NCT02463552	May 2015 → Jun 2016	—	Federal University of Sergipe	Completed	No outcome recorded
—	NCT02388191	Apr 2015 → Apr 2016	—	Planned Parenthood League of Massachusetts	Completed	No outcome recorded
—	NCT02769247	Jun 2014 → Dec 2016	—	Walter Reed National Military Medical Center	Completed	No outcome recorded
—	NCT01982799	Feb 2014 → Sep 2015	tooth disorder	University of Minnesota	Withdrawn	No outcome recorded
—	NCT00789802	Nov 2008 → Jan 2010	hemorrhagic disease	Washington University School of Medicine	Completed	No outcome recorded
—	NCT00536068	Aug 2006 → Aug 2007	vascular hemostatic disease	Kantonsspital Graubünden	Completed	No outcome recorded

Also used as a comparator or background therapy in 167 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT07204379 Comparator	Jan → Jul 2023	—	Armed Forces Institute of Dentistry, Pakistan	Completed	No outcome recorded
Phase 0	NCT03771612 Comparator	Feb 2022 → Nov 2023	—	University of California, Los Angeles	Completed	No outcome recorded
Phase 0	NCT01539447 Comparator	Jan 2012 → Mar 2022	myositis ossificans	University of Utah	Completed	No outcome recorded
Phase 125 trials
Phase 1	NCT05237297 Comparator	Feb → Jul 2022	—	Il-Yang Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04639804 Comparator	Jun → Jul 2020	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT04499209 Comparator	Oct 2017 → Jan 2018	—	Xgene Pharmaceutical Group	Completed	No outcome recorded
Phase 1	NCT02632812 Background	Oct → Nov 2014	—	Biolab Sanus Farmaceutica	Completed	No outcome recorded
Phase 1	NCT02202512 Comparator	Sep → Dec 2014	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02108548 Comparator	Apr 2014 → Mar 2015	—	Astellas Pharma Europe B.V.	Terminated	No outcome recorded
Phase 1	NCT01995006 Comparator	Jan → Apr 2014	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 1	NCT01666678 Comparator	Jan → Feb 2012	—	Bayer	Completed	No outcome recorded
Phase 1	NCT01154790 Comparator	Jun 2010 → Jan 2011	—	CrystalGenomics, Inc.	Completed	No outcome recorded
Phase 1	NCT01404598 Comparator	Jan → Feb 2010	—	NicOx	Completed	No outcome recorded
Phase 1	NCT00907400 Comparator	May → Sep 2009	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00909519 Comparator	Jan → Apr 2009	—	NicOx	Completed	No outcome recorded
Phase 1	NCT00989625 Comparator	Nov 2008 → Sep 2009	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00780325 Comparator	Oct 2008 → Jul 2013	—	University of Pennsylvania	Terminated	No outcome recorded
Phase 1	NCT00761501 Comparator	Sep → Dec 2008	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00750243 Comparator	Sep 2008 → Feb 2009	—	Logical Therapeutics	Completed	No outcome recorded
Phase 1	NCT00743587 Comparator	Sep 2008 → Mar 2009	osteoarthritis, hand	Pfizer	Completed	No outcome recorded
Phase 1	NCT00749385 Comparator	Aug → Oct 2008	arthritic joint disease	POZEN	Completed	No outcome recorded
Phase 1	NCT00692055 Comparator	Jun → Jul 2008	arthritic joint disease	POZEN	Completed	No outcome recorded
Phase 1	NCT00875784 Background	May → Jun 2008	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00665743 Comparator	Mar → Jun 2008	arthritic joint disease	POZEN	Completed	No outcome recorded
Phase 1	NCT00662896 Comparator	Mar → Sep 2008	essential hypertension, osteoarthritis	NicOx	Completed	No outcome recorded
Phase 1	NCT00662610 Comparator	Mar → Aug 2008	essential hypertension, osteoarthritis	NicOx	Completed	No outcome recorded
Phase 1	NCT00599404 Background	Jan → Feb 2008	—	POZEN	Completed	No outcome recorded
Phase 1	NCT00601458 Comparator	Jul 2007 → Jan 2008	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT03493945 Background	May 2018 → Oct 2024	castration-resistant prostate carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT03291418 Comparator	Sep 2017 → Mar 2018	gastric ulcer	Antibe Therapeutics Inc.	Completed	No outcome recorded
Phase 228 trials
Phase 2	NCT06903585 Comparator	Apr 2025 → Apr 2029 expected	bone pain, periodic, metastatic carcinoma in the bone	American University of Beirut Medical Center	Not yet recruiting	No outcome recorded
Phase 2	NCT05087914 Background	Nov 2021 → Dec 2023	—	Northwestern University	Withdrawn	No outcome recorded
Phase 2	NCT05995912 Comparator	Sep 2021 → Aug 2022	—	Laboratorios Liomont	Completed	No outcome recorded
Phase 2	NCT03654326 Background	Sep 2018 → Jun 2020	endometriosis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT03028870 Comparator	Mar → Nov 2017	osteoarthritis, knee	Purdue Pharma LP	Completed	No outcome recorded
Phase 2	NCT02847702 Comparator	Aug → Nov 2016	osteoarthritis, knee	Purdue Pharma LP	Terminated	No outcome recorded
Phase 2	NCT02712957 Comparator	Mar → Nov 2016	osteoarthritis, knee	Neomed Institute	Completed	No outcome recorded
Phase 2	NCT02611466 Comparator	Feb 2016 → Aug 2017	chronic pain syndrome, osteoarthritis, knee	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 2	NCT02262754 Comparator	Oct 2014 → Aug 2015	chronic pain syndrome	Pfizer	Completed	No outcome recorded
Phase 2	NCT02307305 Background	Aug 2014 → Dec 2016	neuropathy, painful	Hanyang University Seoul Hospital	Unknown	No outcome recorded
Phase 2	NCT02128490 Background	May 2014 → Sep 2015	gout	Takeda	Completed	No outcome recorded
Phase 2	NCT02116790 Comparator	May 2014 → Jan 2015	—	Northwestern University	Withdrawn	No outcome recorded
Phase 2	NCT01688934 Comparator	Sep 2012 → Jun 2013	osteoarthritis, knee	Purdue Pharma LP	Completed	No outcome recorded
Phase 2	NCT02702817 Comparator	Aug 2012 → Mar 2017	Alzheimer disease	Douglas Mental Health University Institute	Completed	No outcome recorded
Phase 2	NCT01207115 Comparator	Sep 2010 → May 2011	osteoarthritis, knee	AbbVie	Completed	No outcome recorded
Phase 2	NCT01139190 Comparator	Jul → Dec 2010	peptic ulcer disease	PLx Pharma	Completed	No outcome recorded
Phase 2	NCT01107236 Comparator	Jun → Aug 2010	—	Ironwood Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01160822 Comparator	Apr 2010 → Jul 2011	osteoarthritis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00981357 Comparator	Nov 2009 → May 2010	osteoarthritis, knee	Pfizer	Completed	No outcome recorded
Phase 2	NCT00876187 Comparator	Jun 2009 → Jun 2010	—	Pfizer	Completed	No outcome recorded
Phase 2	NCT00913627 Comparator	May → Aug 2009	—	Pfizer	Completed	No outcome recorded
Phase 2	NCT00672646 Comparator	Apr → Jun 2008	—	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00659490 Comparator	Feb → May 2008	—	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00626275 Comparator	Oct 2007 → Sep 2008	rheumatoid arthritis	Merck & Co., Inc.	Completed	No outcome recorded
Phase 2	NCT00584870 Comparator	Jul 2007 → Sep 2008	—	Pfizer	Completed	No outcome recorded
Phase 2	NCT00418782 Comparator	Jan → Aug 2007	osteoarthritis	Pfizer	Terminated	No outcome recorded
Phase 2	NCT00602901 Background	Jul 2004 → Oct 2006	chronic pain syndrome, subacute bursitis	Palmer College of Chiropractic	Completed	No outcome recorded
Phase 2	NCT02183038 Comparator	Jul 1998 → Feb 1999	pharyngitis	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT05982392 Comparator	Mar → Aug 2023	pulpitis	Dow University of Health Sciences	Completed	No outcome recorded
Phase 2/3	NCT02646124 Background	Jun 2015 → Feb 2016	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 2/3	NCT01442428 Comparator	Jan 2014 → Mar 2016	HIV infectious disease, immune reconstitution inflammatory syndrome, tuberculosis	University of Minnesota	Withdrawn	No outcome recorded
Phase 2/3	NCT01063920 Comparator	Feb → Nov 2010	osteoarthritis	Logical Therapeutics	Completed	No outcome recorded
Phase 334 trials
Phase 3	NCT05761574 Comparator	May 2023 → May 2024	—	Johnson & Johnson Consumer Inc. (J&JCI)	Completed	No outcome recorded
Phase 3	NCT05161221 Comparator	Dec 2021 → Dec 2022	neuropathy, painful	Rothman Institute Orthopaedics	Unknown	No outcome recorded
Phase 3	NCT05154682 Comparator	Nov 2021 → Nov 2022	neuropathy, painful	Rothman Institute Orthopaedics	Unknown	No outcome recorded
Phase 3	NCT03031938 Background	Nov 2017 → Jun 2020	osteoarthritis	Pfizer	Completed	No outcome recorded
Phase 3	NCT02674386 Background	Aug 2016 → Jul 2019	osteoarthritis	Pfizer	Completed	No outcome recorded
Phase 3	NCT01670552 Comparator	Feb → Oct 2016	dyspepsia	EMS	Completed	No outcome recorded
Phase 3	NCT02528188 Comparator	Jul 2015 → Oct 2018	chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee	Pfizer	Completed	No outcome recorded
Phase 3	NCT03658473 Comparator	Nov 2014	stomach disorder	Galeno Desenvolvimento de Pesquisas Clínicas	Completed	No outcome recorded
Phase 3	NCT01726920 Comparator	Jul → Dec 2014	migraine disorder	Ache Laboratorios Farmaceuticos S.A.	Withdrawn	No outcome recorded
Phase 3	NCT02139046 Background	Apr 2014 → Nov 2015	gout	Takeda	Completed	No outcome recorded
Phase 3	NCT01471886 Comparator	Mar → Oct 2013	—	EMS	Completed	No outcome recorded
Phase 3	NCT01471899 Comparator	Mar → Dec 2013	—	EMS	Completed	No outcome recorded
Phase 3	NCT01390324 Comparator	Dec 2011 → Mar 2012	migraine disorder	Ache Laboratorios Farmaceuticos S.A.	Withdrawn	No outcome recorded
Phase 3	NCT01280591 Comparator	Oct 2010 → Jan 2011	—	Bayer	Completed	No outcome recorded
Phase 3	NCT01208207 Comparator	Sep 2010 → Nov 2014	ankylosing spondylitis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00863304 Comparator	Jun 2009 → Apr 2010	osteoarthritis	Pfizer	Completed	No outcome recorded
Phase 3	NCT00830063 Comparator	May 2009 → May 2010	osteoarthritis	Pfizer	Completed	No outcome recorded
Phase 3	NCT01468025 Comparator	Feb → Jul 2009	—	Targeted Medical Pharma	Completed	No outcome recorded
Phase 3	NCT01129011 Comparator	Sep 2007 → Sep 2008	gastric ulcer	POZEN	Completed	No outcome recorded
Phase 3	NCT00527787 Comparator	Sep 2007 → Oct 2008	gastric ulcer	POZEN	Completed	No outcome recorded
Phase 3	NCT00503828 Comparator	Jul 2007 → Mar 2009	osteoarthritis, knee	Mahidol University	Completed	No outcome recorded
Phase 3	NCT00541489 Comparator	Jun 2007 → Sep 2008	osteoarthritis, hip	NicOx	Completed	No outcome recorded
Phase 3	NCT00504127 Comparator	Apr 2007 → Dec 2008	osteoarthritis	NicOx	Completed	No outcome recorded
Phase 3	NCT00367211 Background	Sep 2006 → Sep 2007	ankylosing spondylitis, osteoarthritis	POZEN	Completed	No outcome recorded
Phase 3	NCT00542555 Comparator	Dec 2005 → Sep 2007	osteoarthritis	NicOx	Completed	No outcome recorded
Phase 3	NCT00240617 Comparator	Oct 2005 → Jun 2006	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00240630 Comparator	Oct 2005 → Jun 2006	migraine disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00153660 Comparator	Jun 2005 → Nov 2014	arthritic joint disease, cerebrovascular disorder	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 3	NCT00652808 Comparator	May → Sep 2004	osteoarthritis, knee	Pfizer	Completed	No outcome recorded
Phase 3	NCT00442221 Background	May → Aug 2004	migraine disorder	POZEN	Completed	No outcome recorded
Phase 3	NCT00648258 Comparator	Jul 2003 → Apr 2004	osteoarthritis	Pfizer	Completed	No outcome recorded
Phase 3	NCT00652925 Comparator	Oct 2002 → Apr 2004	juvenile idiopathic arthritis	Pfizer	Completed	No outcome recorded
Phase 3	NCT00092729 Comparator	Jun → Dec 2002	primary dysmenorrhea	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00240773 Comparator	? → Jun 2003	osteoarthritis, hip, osteoarthritis, knee	Johnson & Johnson Consumer and Personal Products Worldwide	Completed	No outcome recorded

Phase 445 trials
Phase 4	NCT07355166 Background	Feb → Jul 2026 overdue	—	University of California, Los Angeles	Not yet recruiting	No outcome recorded
Phase 4	NCT06861920 Comparator	Apr 2025 → Apr 2030 expected	chronic pain syndrome, dysmenorrhea, pelvis syndrome	Endeavor Health	Recruiting	No outcome recorded
Phase 4	NCT06562816 Comparator	Aug → Nov 2024 overdue	—	Dow University of Health Sciences	Recruiting	No outcome recorded
Phase 4	NCT06484192 Comparator	Jun 2024 → Jun 2025	—	Rothman Institute Orthopaedics	Unknown	No outcome recorded
Phase 4	NCT06344195 Comparator	Mar → Apr 2024	dental abscess	Dow University of Health Sciences	Unknown	No outcome recorded
Phase 4	NCT04875702 Comparator	Feb 2024 → Sep 2028 expected	gout	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 4	NCT05851976 Background	Oct 2023 → May 2027 expected	—	Montefiore Medical Center	Recruiting	No outcome recorded
Phase 4	NCT05820685 Background	Jul 2023 → Apr 2024	nervous system injury	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded
Phase 4	NCT06916234 Comparator	Jan → Dec 2023	periodontitis	ibrahim doğru	Completed	No outcome recorded
Phase 4	NCT04990804 Background	Aug 2021 → Feb 2022	spinal cord disorder, substance-related disorder	Vanderbilt University Medical Center	Terminated	No outcome recorded
Phase 4	NCT04129086 Comparator	Jul 2020 → Mar 2022	—	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT04145518 Comparator	Oct 2019 → Jul 2025	endometrial disorder, leiomyoma, primary dysmenorrhea, secondary dysmenorrhea	Endeavor Health	Completed	No outcome recorded
Phase 4	NCT03699293 Comparator	Sep 2018 → Dec 2022	cardiovascular disorder, rheumatoid arthritis	Platelet and Thrombosis Research, LLC	Terminated	No outcome recorded
Phase 4	NCT03472469 Comparator	Apr 2018 → Jul 2019	—	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT02986334 Comparator	Aug 2016 → Jun 2018	chronic pain syndrome	Apkar Apkarian	Completed	No outcome recorded
Phase 4	NCT02689024 Comparator	May 2016 → Jul 2023	—	Academic Medical Center - University of Amsterdam	Terminated	No outcome recorded
Phase 4	NCT02665286 Comparator	Mar 2016 → Apr 2017	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT02519231 Comparator	Feb 2016 → Nov 2017	menstrual disorder	University of Washington	Completed	No outcome recorded
Phase 4	NCT02604550 Comparator	Nov 2015 → Apr 2016	—	Emory University	Completed	No outcome recorded
Phase 4	NCT02500641 Background	Aug 2015 → May 2017	gout	Menarini International Operations Luxembourg SA	Completed	No outcome recorded
Phase 4	NCT02451748 Background	Aug 2015 → Sep 2017	rheumatoid arthritis	University of Illinois at Chicago	Completed	No outcome recorded
Phase 4	NCT01951105 Comparator	Feb 2015 → Sep 2017	subacute bursitis	Northwestern University	Completed	No outcome recorded
Phase 4	NCT02013427 Comparator	Oct 2014 → May 2016	chronic pain syndrome	Northwestern University	Completed	No outcome recorded
Phase 4	NCT02252614 Comparator	Sep → Dec 2014	—	Diskapi Yildirim Beyazit Education and Research Hospital	Unknown	No outcome recorded
Phase 4	NCT01994226 Comparator	Jan 2014 → Mar 2016	gout	Keele University	Completed	No outcome recorded
Phase 4	NCT01952652 Comparator	Jan → Jun 2013	—	Baskent University	Completed	No outcome recorded
Phase 4	NCT01587274 Comparator	Apr 2012 → Oct 2014	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT01525043 Comparator	Feb 2012 → Feb 2013	epicondylitis	International Clinical Research Institute	Completed	No outcome recorded
Phase 4	NCT01329562 Comparator	May 2011 → Jun 2012	migraine disorder	Cady, Roger, M.D.	Completed	No outcome recorded
Phase 4	NCT01300546 Comparator	Dec 2010 → Apr 2012	migraine disorder	Cady, Roger, M.D.	Completed	No outcome recorded
Phase 4	NCT01267825 Comparator	Sep 2010 → Aug 2013	lumbar disk disease, radiculopathy	Montefiore Medical Center	Terminated	No outcome recorded
Phase 4	NCT01090050 Comparator	Sep 2010 → Jun 2012	migraine disorder	Cady, Roger, M.D.	Completed	No outcome recorded
Phase 4	NCT01053507 Comparator	May 2010 → Nov 2012	traumatic encephalopathy	Cady, Roger, M.D.	Terminated	No outcome recorded
Phase 4	NCT01450995 Comparator	Dec 2009 → May 2011	migraine disorder	Stephen H. Landy, M.D.	Completed	No outcome recorded
Phase 4	NCT01086358 Comparator	Sep 2009 → Aug 2016	—	The Cleveland Clinic	Completed	No outcome recorded
Phase 4	NCT01138150 Comparator	Sep 2009 → Jun 2013	migraine disorder	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT01165307 Comparator	Aug 2009 → Sep 2015	menstrual disorder	Abimbola Famuyide	Completed	No outcome recorded
Phase 4	NCT01374269 Comparator	Jun 2009 → Oct 2011	—	Grupo Rehabilitacion en Salud	Completed	No outcome recorded
Phase 4	NCT00826462 Background	Mar 2009 → Jun 2013	epicondylitis	University of Oslo	Completed	No outcome recorded
Phase 4	NCT00615875 Comparator	Mar → May 2008	—	Hamilton Health Sciences Corporation	Unknown	No outcome recorded
Phase 4	NCT00778193 Comparator	Oct 2007 → Mar 2008	peptic ulcer disease	Research Associates of New York, LLP	Completed	No outcome recorded
Phase 4	NCT00449787 Comparator	Mar 2007 → Jul 2009	migraine disorder	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT00346216 Comparator	Oct 2006 → Apr 2016	rheumatoid arthritis	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00643799 Comparator	Mar 2004 → Jan 2005	osteoarthritis, knee	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00650455 Comparator	Feb 2003 → Jan 2005	rheumatoid arthritis	Pfizer	Completed	No outcome recorded

Phase not applicable26 trials
—	NCT07493226 Comparator	Apr 2026 → Feb 2027 expected	frozen shoulder, neuropathy, painful	Konya Beyhekim Training and Research Hospital	Recruiting	No outcome recorded
—	NCT04572828 Comparator	Sep → Nov 2020	—	Ege University	Completed	No outcome recorded
—	NCT04236908 Background	Aug 2020 → Dec 2025	—	David Moss	Completed	No outcome recorded
—	NCT04463420 Background	Aug → Nov 2020	COVID-19	Baqiyatallah Medical Sciences University	Unknown	No outcome recorded
—	NCT04183556 Comparator	Nov 2019 → Apr 2020	primary dysmenorrhea	Batman Training and Research Hospital	Completed	No outcome recorded
—	NCT03794219 Background	Jan → Jul 2019	epicondylitis	Ankara Education and Research Hospital	Completed	No outcome recorded
—	NCT04296422 Comparator	Jan 2019 → Sep 2020	premenstrual tension	Taipei City Hospital	Unknown	No outcome recorded
—	NCT03727412 Comparator	Aug 2018 → Oct 2021	abdominal aortic aneurysm	University of Thessaly	Unknown	No outcome recorded
—	NCT03881319 Comparator	Jun 2018 → Dec 2019	dysmenorrhea, premenstrual tension	Taipei City Hospital	Unknown	No outcome recorded
—	NCT03351439 Background	Apr 2018 → Sep 2021	chronic pain syndrome	Western University, Canada	Completed	No outcome recorded
—	NCT02643719 Comparator	Dec 2015 → Oct 2017	migraine disorder	NYU Langone Health	Withdrawn	No outcome recorded
—	NCT02522130 Comparator	Jul 2015 → Dec 2016	—	Al Hayat National Hospital	Unknown	No outcome recorded
—	NCT02786446 Comparator	Jul 2015 → Jan 2016	urolithiasis	Shifa International Hospital	Completed	No outcome recorded
—	NCT02132416 Comparator	May 2014 → Jun 2017	—	Sahlgrenska University Hospital	Completed	No outcome recorded
—	NCT02094807 Background	Apr 2014 → May 2020	—	Sahlgrenska University Hospital	Withdrawn	No outcome recorded
—	NCT01638962 Comparator	Aug 2012 → Aug 2015	osteoarthritis, knee	University of Southern Denmark	Completed	No outcome recorded
—	NCT01511627 Background	Jan → Jul 2012	—	University of Saskatchewan	Withdrawn	No outcome recorded
—	NCT01557816 Comparator	Dec 2011 → Jun 2012	osteoarthritis, knee	Analgesic Solutions	Unknown	No outcome recorded
—	NCT00893594 Comparator	Oct 2010 → Dec 2015	migraine with aura	Dent Neurologic Institute	Unknown	No outcome recorded
—	NCT00837044 Comparator	Feb → Jul 2009	cognitive disorder, migraine disorder	Neurological Research Center	Unknown	No outcome recorded
—	NCT00790985 Comparator	Jan → Aug 2008	osteoarthritis, knee	Primus Pharmaceuticals	Completed	No outcome recorded
—	NCT01090596 Comparator	Apr 2007 → Jun 2008	—	Research Associates of New York, LLP	Completed	No outcome recorded
—	NCT01165814 Comparator	Aug 2006 → Mar 2009	—	Bnai Zion Medical Center	Completed	No outcome recorded
—	NCT00435292 Comparator	Apr 2006 → Dec 2007	osteoarthritis	Primus Pharmaceuticals	Completed	No outcome recorded
—	NCT00303017 Comparator	Mar → Jul 2006	osteoarthritis	Primus Pharmaceuticals	Completed	No outcome recorded
—	NCT00928837 Comparator	Mar 2006 → Jun 2007	osteoarthritis, knee	Primus Pharmaceuticals	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2016-11-13	Pfizer	Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen pfizer.com ↗

Evidence & citations 59 cited values

Every value below carries the sentence it was read from. 318 sources stand behind the page.

Field	Value	Cited text
Known as	Naproxen	“The aim of the present randomized placebo-controlled study is to evaluate whether the perioperative administration of Naproxen (NPR) an anti-inflammatory drug with a beneficial...” NCT03727412 ↗ 272 “An Open-Label, Randomized, Four-Way Crossover Study to Evaluate the Effect of Food on the Bioavailability of Naproxen and Esomeprazole From a PN 400 Tablet in Healthy Subjects” NCT00676442 ↗ “One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.” NCT01138150 ↗ “Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.” PMID 21319944 ↗ Feb 2011 “The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications.” NCT01374269 ↗ “Patients randomized into this group (n=40) will, again by simple randomization, be given oral tablets of ibuprofen or naproxen” NCT07493226 ↗ “coadministered enteric-coated naproxen 500 mg and immediate-release esomeprazole magnesium 20 mg (fixed-dose combination)” PMID 22078153 ↗ Nov 2011 “PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).” NCT00594854 ↗ “IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.” NCT02674386 ↗ “IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study” NCT03031938 ↗ “Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks” NCT02528188 ↗ “* Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)” NCT05722002 ↗ “NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.” NCT03881319 ↗ “already marketed formulation of prescription strength naproxen (Naprosyn® the reference product)” NCT02408978 ↗ “with sumatriptan-naproxen (Treximet®) or placebo in a double-blind, placebo-controlled fashion” PMID 23406052 ↗ Feb 2013 “500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9” NCT00599404 ↗ “Aleve® naproxen sodium, a Reference product currently marketed in The Netherlands” NCT03167541 ↗ “Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks” NCT00809354 ↗ “single-tablet naproxen 500 mg/esomeprazole 20 mg (NAP/ESO) given twice daily” PMID 26313454 ↗ Aug 2015 “Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks” NCT05021718 ↗ “PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium” NCT04221165 ↗ “NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam.” NCT04296422 ↗ “A prescription for Naproxen 500mg PO BID PRN x 60 tabs” NCT04566250 ↗ “Medications: Ibuprofen, Naproxen, or Diclofenac.” NCT06453291 ↗ “Naproxen 500mg by mouth twice a day as needed.” NCT04236908 ↗ “Naproxen 500 mg dosed twice daily (bid) orally” NCT01129011 ↗ “one naproxen 250 mg every 12 hours for 5 days” NCT04463420 ↗ “TREXIMET® (Sumatriptan + Naproxen Sodium)” NCT00573170 ↗ “a 14-day supply of 500mg naproxen BID” NCT07355166 ↗ “Naproxen: po, 500mg, bid, six weeks.” NCT00602901 ↗ “500mg Naproxen and 20mg esomeprazole” NCT00992381 ↗ “Naproxen + Oxycodone/ Acetaminophen” NCT01267825 ↗ “Naproxen 500 mg po q12 hours” NCT04129086 ↗ “PN 200 (Omeprazole/Naproxen)” NCT00442208 ↗ “Naproxen® 500 mg per os” NCT01511627 ↗ “Naproxen sodium 220mg” NCT03183297 ↗ “Naproxen 500mg BID” NCT04139824 ↗ “Naproxen” NCT04139824 ↗ “Naproxen” NCT01638962 ↗ NCT00329459 ↗ NCT01557816 ↗ NCT01982799 ↗ NCT01525043 ↗ NCT04307940 ↗ NCT00945178 ↗ NCT02611466 ↗ NCT06903585 ↗ NCT00672646 ↗ NCT00692055 ↗ NCT02281968 ↗ NCT02202512 ↗ NCT02451748 ↗ NCT03028870 ↗ NCT01659372 ↗ NCT05430230 ↗ NCT01952652 ↗ NCT01178203 ↗ NCT00830063 ↗ NCT00830050 ↗ NCT00907400 ↗ NCT00643799 ↗ NCT01427803 ↗ NCT00303017 ↗ NCT03472469 ↗ NCT06916234 ↗ NCT01994226 ↗ NCT00137033 ↗ NCT02463552 ↗ NCT00772967 ↗ NCT00488514 ↗ NCT00652808 ↗ NCT02986334 ↗ NCT01995006 ↗ NCT01208207 ↗ NCT04115098 ↗ NCT06917118 ↗ NCT01118273 ↗ NCT00789802 ↗ NCT04132336 ↗ NCT00743587 ↗ NCT04572828 ↗ NCT02139046 ↗ NCT00659490 ↗ NCT06415019 ↗ NCT05237297 ↗ NCT02702817 ↗ NCT02667730 ↗ NCT00527787 ↗ NCT02712957 ↗ NCT00586365 ↗ NCT01207115 ↗ NCT01939002 ↗ NCT01343303 ↗ NCT05161221 ↗ NCT02494856 ↗ NCT06948513 ↗ NCT06861920 ↗ NCT01951105 ↗ NCT01404598 ↗ NCT02501564 ↗ NCT02500641 ↗ NCT00650455 ↗ NCT00383162 ↗ NCT02502006 ↗ NCT00662610 ↗ NCT02355236 ↗ NCT00584870 ↗ NCT00261586 ↗ NCT00843024 ↗ NCT00662896 ↗ NCT01712009 ↗ NCT03347929 ↗ NCT02013427 ↗ NCT01160822 ↗ NCT02262754 ↗ NCT00652925 ↗ NCT06484192 ↗ NCT02128490 ↗ NCT02632812 ↗ NCT01666678 ↗ NCT00366262 ↗ NCT07549490 ↗ NCT00863304 ↗ NCT00346216 ↗ NCT00433732 ↗ NCT04183556 ↗ NCT00004845 ↗ NCT00844805 ↗ NCT02388191 ↗ NCT01365052 ↗ NCT01231490 ↗ NCT02108548 ↗ NCT01688934 ↗ NCT05026320 ↗ NCT00959439 ↗ NCT03448536 ↗ NCT01090050 ↗ NCT02519231 ↗ NCT03794219 ↗ NCT04490434 ↗ NCT01884272 ↗ NCT02522130 ↗ NCT00385008 ↗ NCT00749385 ↗ NCT03570554 ↗ NCT05087914 ↗ NCT05181124 ↗ NCT04038346 ↗ NCT00602420 ↗ NCT03493945 ↗ NCT00792636 ↗ NCT00175032 ↗ NCT00449787 ↗ NCT00392080 ↗ NCT00503828 ↗ NCT01468025 ↗ NCT00367211 ↗ NCT00536068 ↗ NCT05463367 ↗ NCT03654326 ↗ NCT00751400 ↗ NCT00909519 ↗ NCT03949673 ↗ NCT00928837 ↗ NCT07706036 ↗ NCT01539447 ↗ NCT00751556 ↗ NCT01229228 ↗ NCT02307305 ↗ NCT06435442 ↗ NCT03566979 ↗ NCT01670552 ↗ NCT01280591 ↗ NCT00034853 ↗ NCT05820685 ↗ NCT00504127 ↗ NCT04384367 ↗ NCT00913627 ↗ NCT02643719 ↗ NCT00387881 ↗ NCT00541489 ↗ NCT00434083 ↗ NCT01409603 ↗ NCT03658473 ↗ NCT02847702 ↗ NCT01726920 ↗ NCT00435292 ↗ NCT00761501 ↗ NCT03424135 ↗ NCT05411718 ↗ NCT00542555 ↗ NCT00665743 ↗ NCT00240773 ↗ NCT03771612 ↗ NCT01102660 ↗ NCT06274151 ↗ NCT00240630 ↗ NCT05851976 ↗ NCT00240617 ↗ NCT01154790 ↗ NCT04325633 ↗ NCT07487909 ↗ NCT06511973 ↗ NCT01587274 ↗ NCT04694300 ↗ NCT03699293 ↗ NCT03879408 ↗ NCT01090596 ↗ NCT03396250 ↗ NCT02183038 ↗ NCT00826462 ↗ NCT01495858 ↗ NCT00279747 ↗ NCT00807846 ↗ NCT00626275 ↗ NCT03404206 ↗ NCT02646124 ↗ NCT04499209 ↗ NCT04447040 ↗ NCT05900336 ↗ NCT02786446 ↗ NCT03697889 ↗ NCT03401177 ↗ NCT03161093 ↗ NCT05995912 ↗ NCT04948164 ↗ NCT00153660 ↗ NCT00876187 ↗ NCT05541185 ↗ NCT00418782 ↗ NCT07606638 ↗ NCT00981357 ↗ NCT03697720 ↗ NCT04947566 ↗ NCT04875702 ↗ NCT05844995 ↗ NCT00222976 ↗ NCT07204379 ↗ NCT01358383 ↗ NCT02665286 ↗ NCT04449471 ↗ NCT01390324 ↗ NCT02052908 ↗ NCT07665476 ↗ NCT01139190 ↗ NCT05761574 ↗ NCT04639804 ↗ NCT00157872 ↗ NCT01612975 ↗ NCT02769247 ↗ NCT02689024 ↗ NCT02116790 ↗ NCT01071317 ↗ NCT00410995 ↗ NCT00007189 ↗ NCT04145518 ↗ NCT03092193 ↗ NCT01442428 ↗ NCT00933582 ↗ NCT00989625 ↗ NCT05154682 ↗ NCT00780325 ↗ NCT01471899 ↗ NCT07277712 ↗ NCT00778193 ↗ NCT00615875 ↗ NCT01147458 ↗ NCT01165814 ↗ NCT00790985 ↗ NCT06291337 ↗ NCT02229461 ↗ NCT01471886 ↗ NCT00648258 ↗
Known as	Aleve	“Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica” NCT04499209 ↗ 10 “Aleve® naproxen sodium, a Reference product currently marketed in The Netherlands” NCT03167541 ↗ “Drug: Naproxen Sodium IR (Aleve, BAYH6689)” NCT01389284 ↗ “1x 220 mg naproxen sodium (Aleve caplet)” NCT00913627 ↗ “Naproxen Sodium (Aleve, BAY117031)” NCT03404206 ↗ “Naproxen Sodium (Aleve, BAY117031)” NCT03570554 ↗ “Naproxen Sodium (Aleve, BAYH6689)” NCT01666678 ↗ “Aleve: po, 220mg, bid, six weeks” NCT00602901 ↗ “Naproxen Sodium (Aleve)” NCT00007189 ↗ “Naproxen sodium (Aleve)” NCT05485805 ↗ NCT01450995 ↗
Known as	Anaprox	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Anaprox ds	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Arthrosin 250	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Arthrosin 250 ec	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Arthrosin 500	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Arthrosin 500 ec	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	BAY117031	“Naproxen Sodium (Aleve, BAY117031)” NCT03404206 ↗ 1 “Naproxen Sodium (Aleve, BAY117031)” NCT03570554 ↗
Known as	BAYH006689	“Naproxen (BAYH006689)” NCT06511973 ↗ 1 “Naproxen (BAYH006689)” NCT06415019 ↗
Known as	BAYH6689	“Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain” NCT01383486 ↗ 8 “Drug: Naproxen Sodium ER (BAYH6689)” NCT00720057 ↗ “Drug: Naproxen Sodium ER (BAYH6689)” NCT01389284 ↗ “Naproxen sodium 440 mg (BAYH6689)” NCT01280591 ↗ “Naproxen Sodium (Aleve, BAYH6689)” NCT01666678 ↗ “Naproxen Sodium 440 mg (BAYH6689)” NCT01118273 ↗ “Naproxen Sodium ER (BAYH6689)” NCT01427803 ↗ “Naproxen sodium ER (BAYH6689)” NCT00818415 ↗ “Naproxen Sodium ER (BAYH6689)” NCT00751400 ↗
Known as	Bonyl	“Bonyl/ Naproxen 500 mg x 2 per day for 7 days” NCT06274151 ↗
Known as	Condrotec	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Ec-naprosyn	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	EC-Narosyn	“Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)” NCT00959439 ↗
Known as	Feminax ultra	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Grenoxal	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Kenosyn	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Laraflex	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Napratec op	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naprelan	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naprosyn	“patients with an abdominal aortic aneurysm undergoing endovascular epair and taking preoperatively naproxen (Naprosyn, tab 500 mg twice/day for 4 days)” NCT03727412 ↗ 9 “already marketed formulation of prescription strength naproxen (Naprosyn® the reference product)” NCT02408978 ↗ “Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID)” NCT04990804 ↗ “Naprosyn” NCT02132416 ↗ “Naprosyn” NCT02094807 ↗ NCT00893594 ↗ NCT03351439 ↗ NCT00750243 ↗ NCT02604550 ↗ NCT01063920 ↗
Known as	Naprosyn 375	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naprosyn ec	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	NAPROXEN COMPONENT OF PN400	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naproxen component of vimovo	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naproxen sodium	“Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets” NCT00596245 ↗ 48 “Naproxen Sodium is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief and inflammation reduction.” NCT06861920 ↗ “ComboProduct Containing Sumatriptan and Naproxen Sodium for Acute Treatment of Migraine in Adolescents” NCT01016678 ↗ “Aleve® naproxen sodium, a Reference product currently marketed in The Netherlands” NCT03167541 ↗ “Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.” NCT01329562 ↗ “Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)” NCT03396250 ↗ “novel combination naproxen sodium (NS) and diphenhydramine (DPH)” PMID 25996289 ↗ May 2015 “treated With Naproxen Sodium (440mg Twice Daily) Versus Placebo” NCT02519231 ↗ “Combination Product (sumatriptan succinate / naproxen sodium)” NCT00385008 ↗ “Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium” NCT01086358 ↗ “sumatriptan succinate / naproxen sodium tablet” NCT00875784 ↗ “Naproxen Sodium will be administered orally.” NCT05761574 ↗ “Acetaminophen (APAP)/Naproxen sodium (NPX)” NCT04447040 ↗ “1x 220 mg naproxen sodium (Aleve caplet)” NCT00913627 ↗ “Naproxen Sodium (Aleve, BAY117031)” NCT03404206 ↗ “Treatment B- Naproxen sodium 220mg” NCT07487909 ↗ “Naproxen Sodium (Aleve, BAY117031)” NCT03570554 ↗ “Naproxen Sodium (Aleve, BAYH6689)” NCT01666678 ↗ “Naproxen Sodium 440 mg (BAYH6689)” NCT01118273 ↗ “Naproxen Sodium ER (BAYH6689)” NCT00751400 ↗ “MT 400, naproxen sodium 550mg” NCT00596245 ↗ “Naproxen Sodium (Aleve)” NCT00007189 ↗ NCT00692016 ↗ NCT00893737 ↗ NCT01383486 ↗ NCT00382993 ↗ NCT06562816 ↗ NCT01053507 ↗ NCT06344195 ↗ NCT00092729 ↗ NCT02255955 ↗ NCT01107236 ↗ NCT02252614 ↗ NCT04066426 ↗ NCT05868122 ↗ NCT01389284 ↗ NCT00329355 ↗ NCT05485805 ↗ NCT00720057 ↗ NCT00818415 ↗ NCT04015596 ↗ NCT05845008 ↗ NCT00969449 ↗ NCT00601458 ↗ NCT01165307 ↗ NCT03291418 ↗ NCT00442221 ↗ NCT05982392 ↗ NCT01300546 ↗
Known as	Naproxen sodium anhydrous	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naproxen sodium component of aleve-d	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naproxen sodium component of treximet	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naproxen Sodium ER	“Naproxen Sodium ER (BAYH6689)” NCT01427803 ↗
Known as	Naproxen sodium salt	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naproxene	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Naproxeno	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	NAPSO	“This study evaluated the time to rescue medication following a single dose of naproxen sodium (NAPSO) vs ibuprofen (IBU) and placebo in subjects with moderate-to-severe...” PMID 31402718 ↗ Aug 2019
Known as	NPR	“the patients will be randomly selected to receive either Naproxen (NPR ) 500 mg x 2 or placebo” NCT03727412 ↗
Known as	NPX	“Acetaminophen (APAP)/Naproxen sodium (NPX)” NCT04447040 ↗
Known as	NSC-750183	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	NSC-757239	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Nycopren	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	OXP005	“The Sponsor is developing a new form of naproxen (the study drug, OXP005), for the potential treatment of rheumatic and painful conditions.” NCT02351024 ↗ 2 “a new naproxen tablet formulation (the study drug, OXP005)” NCT02408978 ↗ NCT02351024 ↗
Known as	Pranoxen continus	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Prosaid	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Proxen S	“Naproxen (Proxen S)” NCT06903585 ↗
Known as	RB naproxen sodium	“support the registration of the Reckitt Benckiser (RB) naproxen sodium (220 mg tablets)” NCT03167541 ↗
Known as	Rheuflex 250	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Rheuflex 500	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Rimoxyn	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	RS-3540	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	RS-3650	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Stirlescent	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Synflex	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Timpron	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Timpron 250 ec	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Known as	Timpron 500 ec	ChEMBL registry synonym — accepted as the source's own label CHEMBL154 ↗
Action	Inhibit	“Inhibitory Effect of CG100649, Celecoxib, Naproxen, and Acetazolamide on the Activity of Cyclooxygenases (COX-1, COX-2) and Carbonic Anhydrases (CA-I, CA-II)” NCT00780325 ↗
Modality	Small molecule	“the conventional NSAID naproxen sodium” PMID 17111043 ↗ Nov 2006
Route	Oral	“naproxen oral suspension” NCT00034853 ↗
Target	TAS1R3	“The sweet taste receptor, TAS1R2-TAS1R3, is expressed both orally, where it signals sweet taste, and extraorally in the intestine and pancreas, where it may affect glucose...” NCT06291337 ↗